Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 10 October 2005. doi:10.1136/hrt.2005.061622
Heart 2006;92:641-649
Copyright © 2006 BMJ Publishing Group Ltd & British Cardiovascular Society

INTERVENTIONAL CARDIOLOGY AND SURGERY

Drug eluting stents: an updated meta-analysis of randomised controlled trials

C Roiron1, P Sanchez2, A Bouzamondo2, P Lechat2, G Montalescot1

1 Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
2 Service de Pharmacologie Clinique, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

Correspondence to:
Dr Gilles Montalescot
Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 Bd de l’Hôpital, 75013 Paris, France; gilles.montalescot{at}psl.ap-hop-paris.fr

Objective: To confirm the overall benefit of drug eluting stents (DES), to evaluate the effect of different DES, and to assess the global safety of DES compared with bare stents through a meta-analysis of randomised controlled trials.

Methods: Randomised controlled trials comparing sirolimus and derivates or paclitaxel and derivates eluting stents versus bare stents. Binary restenosis and major adverse cardiac events (MACE) were chosen as primary end points. Death, Q wave myocardial infarction (MI), and stent thrombosis up to 12 months’ follow up were also analysed.

Results: MACE overall occurrence was highly reduced with DES from 19.9% to 10.1% (odds ratio (OR) 0.46, 95% confidence interval (CI) 0.41 to 0.52, p < 0.001). A significant heterogeneity (p < 0.001) was found between subgroups according to the drug: MACE OR was 0.28 (95% CI 0.22 to 0.35) in the sirolimus subgroup and 0.62 (95% CI 0.53 to 0.73) in the paclitaxel subgroup. Restenosis was also highly reduced from 31.7% with bare stents to 10.5% with DES (OR 0.25, 95% CI 0.22 to 0.29, p < 0.001) with a similar heterogeneity between subgroups. Mortality, Q wave MI, and stent thrombosis were not significantly different between DES and control group, whereas Q wave MI and stent thrombosis tended to be more frequent with paclitaxel.

Conclusion: This meta-analysis confirms the overall benefit of DES on restenosis and MACE with significant heterogeneity between drugs, suggesting higher efficacy of sirolimus eluting stents. Additional data with longer follow up and in high risk populations are needed to clarify issues on stent thrombosis.

Abbreviations: CI, confidence interval; DES, drug eluting stents; ENDEAVOR, randomised, controlled trial of the Medtronic Endeavor drug (ABT-578) eluting coronary stent system versus the Taxus paclitaxel eluting coronary stent system in de novo native coronary artery lesions; FDA, Food and Drug Administration; MACE, major adverse cardiac events; MI, myocardial infarction; OR, odds ratio; SCORE, study to compare restenosis rate between quest and quads-QP2; SIRIUS, sirolimus eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions

Keywords: drug eluting stents; meta-analysis; coronary stenting; sirolimus; paclitaxel


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Web Top 10
Heart 2006 92: 1150. [Extract] [Full Text] [PDF]

WEB TOP 10
Heart 2006 92: 974. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Kim, W.-J., Park, D.-W., Yun, S.-C., Lee, J.-Y., Lee, S.-W., Kim, Y.-H., Lee, C. W., Park, S.-W., Park, S.-J. (2009). Impact of Diabetes Mellitus on the Treatment Effect of Percutaneous or Surgical Revascularization for Patients With Unprotected Left Main Coronary Artery Disease: A Subgroup Analysis of the MAIN-COMPARE Study. J Am Coll Cardiol Intv 2: 956-963 [Abstract] [Full Text]  
  • Di Lorenzo, E., Sauro, R., Varricchio, A., Carbone, G., Cortese, G., Capasso, M., Lanzillo, T., Manganelli, F., Mariello, C., Siano, F., Pagliuca, M. R., Stanco, G., Rosato, G., De Luca, G. (2009). Long-Term Outcome of Drug-Eluting Stents Compared With Bare Metal Stents in ST-Segment Elevation Myocardial Infarction: Results of the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 120: 964-972 [Abstract] [Full Text]  
  • Di Lorenzo, E., De Luca, G., Sauro, R., Varricchio, A., Capasso, M., Lanzillo, T., Manganelli, F., Mariello, C., Siano, F., Pagliuca, M. R., Stanco, G., Rosato, G. (2009). The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. J Am Coll Cardiol Intv 2: 515-523 [Abstract] [Full Text]  
  • Di Mauro, M., Contini, M., Iaco, A. L., Bivona, A., Gagliardi, M., Varone, E., Bosco, P., Calafiore, A. M. (2009). Bilateral internal thoracic artery on the left side: A propensity score-matched study of impact of the third conduit on the right side. J. Thorac. Cardiovasc. Surg. 137: 869-874 [Abstract] [Full Text]  
  • Rademacher, W., Knape, A., Schumm, J., Ferrari, M., Lauten, A., Mudra, H., Figulla, H. R. (2008). Acute and long-term outcome of unprotected left main coronary angioplasty compared to the anticipated surgical risk. ICVTS 7: 871-877 [Abstract] [Full Text]  
  • Mehilli, J., Byrne, R. A., Wieczorek, A., Iijima, R., Schulz, S., Bruskina, O., Pache, J., Wessely, R., Schomig, A., Kastrati, A., for the Intracoronary Stenting and Angiographic Re, (2008). Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 29: 1975-1982 [Abstract] [Full Text]  
  • Kip, K. E., Hollabaugh, K., Marroquin, O. C., Williams, D. O. (2008). The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.. J Am Coll Cardiol 51: 701-707 [Abstract] [Full Text]  
  • Melikian, N, Wijns, W (2008). Drug-eluting stents: a critique. Heart 94: 145-152 [Abstract] [Full Text]  
  • Zeymer, U., Zahn, R. (2007). Drug-eluting stents: effective and safe for every patient and every lesion?. Eur Heart J 28: 2559-2560 [Full Text]  
  • Mark, D. B (2007). Percutaneous coronary revascularisation: is it ever worth what it costs?. Heart 93: 1161-1163 [Full Text]  
  • Stone, G. W., Ellis, S. G., Colombo, A., Dawkins, K. D., Grube, E., Cutlip, D. E., Friedman, M., Baim, D. S., Koglin, J. (2007). Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation. Circulation 115: 2842-2847 [Abstract] [Full Text]  
  • Maeng, M., Okkels Jensen, L., Rasmussen, K., Flensted Lassen, J., Romer Krusell, L., Thayssen, P., Thuesen, L. (2007). Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. Heart 93: 694-697 [Abstract] [Full Text]  
  • Luthra, S., Tatoulis, J., Warren, R. J. (2007). Drug-Eluting Stent-Induced Left Anterior Descending Coronary Artery Aneurysm: Repair by Pericardial Patch--Where Are We Headed?. Ann. Thorac. Surg. 83: 1530-1532 [Abstract] [Full Text]  
  • Rao, C., Aziz, O., Panesar, S. S., Jones, C., Morris, S., Darzi, A., Athanasiou, T. (2007). Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 334: 621-621 [Abstract] [Full Text]  
  • Esaki, J., Koshiji, T., Okamoto, M., Tsukashita, M., Ikuno, T., Sakata, R. (2007). Gastroepiploic Artery Grafting Does Not Improve the Late Outcome in Patients With Bilateral Internal Thoracic Artery Grafting. Ann. Thorac. Surg. 83: 1024-1029 [Abstract] [Full Text]  
  • Szotowski, B., Antoniak, S., Goldin-Lang, P., Tran, Q.-V., Pels, K., Rosenthal, P., Bogdanov, V. Y., Borchert, H.-H., Schultheiss, H.-P., Rauch, U. (2007). Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc Res 73: 806-812 [Abstract] [Full Text]  
  • Van Brabandt, H. (2007). Stent thrombosis: Antiplatelets alone won't do the job. BMJ 334: 57-57 [Full Text]  
  • Pislaru, S. V., Harbuzariu, A., Gulati, R., Witt, T., Sandhu, N. P., Simari, R. D., Sandhu, G. S. (2006). Magnetically Targeted Endothelial Cell Localization in Stented Vessels. J Am Coll Cardiol 48: 1839-1845 [Abstract] [Full Text]  
  • Boccara, F, Teiger, E, Cohen, A (2006). Role of drug eluting stents in diabetic patients. Heart 92: 579-581 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.